VentureTECH recently signed a tripartite MoU with with Duopharma Biotech Bhd and PanGen Biotech Inc. toward the establishment of Malaysia’s first commercial biosimilar production facility in a move to position the country as a regional player in the growing biosimilar market. The move will also benefit a greater portion of patients as it will improve the affordability and accessibility of healthcare in the country. VentureTECH will invest RM15 million into a joint venture between Duopharma Biotech a Malaysian leading pharmaceutical company and PanGen, a South Korea-based company that specializes in research and manufacturing of bio-based medicine to produce biosimilar drugs to cater to both domestic and export market as well as building local capacity to produce biosimilar products. The MoU signing ceremony in Zanith Hotel, Putrajaya was graced and witnessed by the Minister of Science, Technology, and Innovation (MOSTI), YB Khairy Jamaluddin.